MedTrace Logo

A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland

NCT01531621 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2015-03-26

No results posted yet for this study

Summary

* A population-based prospective study to evaluate clinical behaviour, resectability and survival in 1st line metastatic colorectal cancer (CRC) patients in Finland
* Primary objective: To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection
* Secondary objectives: To assess treatments for mCRC; To assess efficacy of chemotherapy and targeted drugs with overall response rates (ORR), failure free survival (FFS), progression free survival (PFS), and overall survival (OS); To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria; To evaluate whole blood, plasma, serum and tumour block biomarkers and DNA polymorphisms that may predict drug effects, resectability and clinical behaviour of the tumour

Conditions

Interventions

OTHER

Biomarker sampling

Blood samples every 8-12 weeks

Sponsors & Collaborators

  • Pia Osterlund

    lead OTHER

Principal Investigators

  • Pia Osterlund, MD · Helsinki University Central Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531621 on ClinicalTrials.gov